PMA device
Advia Centaur Afp Assay
Siemens Healthcare Diagnostics, Inc. · Kit, Test, Alpha-Fetoprotein For Neural Tube Defects (LOK, Class III) · First FDA decision Oct 15, 2012, newest Apr 13, 2018Genetic and newborn screening
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Advia Centaur Afp"
MAUDE reports
2
Brand "Advia Centaur Afp", since 2015
PubMed studies
0
Mentioning "Advia Centaur Afp"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Advia Centaur Afp Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- ADVIA CENTAUR AFP ASSAYPMA supplement
P930036-S006 · Decided Apr 13, 2018 · 1,001 days after receipt · Normal 180 Day Track
Device type: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS (LOK) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Advia Centaur Afp", any status and sponsor, newest update first.
No registered device study names "Advia Centaur Afp".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Advia Centaur Afp", and for the whole product code for context.
This brand
2 reports: 2 malfunction, 0 injury, 0 death
Whole product code LOK
140 reports: 140 malfunction, 0 injury, 0 death
Newest reports for this brand
- ADVIA CENTAUR AFPMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS INC.
1219913-2024-00186 · Received Mar 20, 2024 · Event dated Feb 1, 2024
Device type: Kit, Test,Alpha-Fetoprotein For Testicular Cancer (LOJ)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Advia Centaur Afp"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LOK.
- Access AFP (on DxI 9000 Analyzer)Beckman Coulter, Inc. · PMA 2025
- Architect AfpAbbott Laboratories · PMA 2020
- Atellica IM Alpha Fetoprotein (AFP)Siemens Healthcare Diagnostics, Inc. · PMA 2024
- Axsym AfpAbbott Laboratories · PMA 2011
- Alinity i AFPAbbott Laboratories · PMA 2020
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 AfpSiemens Healthcare Diagnostics, Inc. · PMA 2010
- Immulite 2000 AfpSiemens Healthcare Diagnostics, Inc. · PMA 2026
- ARCHITECT AFP, Alinity i AFPAbbott Laboratories · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.